KR20160079781A - 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제 - Google Patents

매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제 Download PDF

Info

Publication number
KR20160079781A
KR20160079781A KR1020167010042A KR20167010042A KR20160079781A KR 20160079781 A KR20160079781 A KR 20160079781A KR 1020167010042 A KR1020167010042 A KR 1020167010042A KR 20167010042 A KR20167010042 A KR 20167010042A KR 20160079781 A KR20160079781 A KR 20160079781A
Authority
KR
South Korea
Prior art keywords
antimicrobial agent
nanoparticles
diameter
agent
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167010042A
Other languages
English (en)
Korean (ko)
Inventor
다카히로 다다
가즈히로 가가미
시로 요코타
겐타 기쿠치
Original Assignee
액티버스 파마 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액티버스 파마 컴퍼니 리미티드 filed Critical 액티버스 파마 컴퍼니 리미티드
Priority to KR1020217013681A priority Critical patent/KR102345084B1/ko
Publication of KR20160079781A publication Critical patent/KR20160079781A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020167010042A 2013-11-08 2014-11-07 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제 Ceased KR20160079781A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217013681A KR102345084B1 (ko) 2013-11-08 2014-11-07 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013231796 2013-11-08
JPJP-P-2013-231796 2013-11-08
PCT/JP2014/005603 WO2015068397A1 (ja) 2013-11-08 2014-11-07 マクロライド系抗菌剤のナノ微粒子を含有する水性懸濁液剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013681A Division KR102345084B1 (ko) 2013-11-08 2014-11-07 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제

Publications (1)

Publication Number Publication Date
KR20160079781A true KR20160079781A (ko) 2016-07-06

Family

ID=53041191

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167010042A Ceased KR20160079781A (ko) 2013-11-08 2014-11-07 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제
KR1020217013681A Active KR102345084B1 (ko) 2013-11-08 2014-11-07 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217013681A Active KR102345084B1 (ko) 2013-11-08 2014-11-07 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제

Country Status (16)

Country Link
US (1) US10792248B2 (enExample)
EP (1) EP3067045B1 (enExample)
JP (1) JP6407882B2 (enExample)
KR (2) KR20160079781A (enExample)
CN (1) CN105658203B (enExample)
AU (1) AU2014345193C1 (enExample)
BR (1) BR112016010358B1 (enExample)
CA (1) CA2929361C (enExample)
ES (1) ES3003920T3 (enExample)
IL (1) IL245406B (enExample)
MX (1) MX2016005764A (enExample)
PL (1) PL3067045T3 (enExample)
PT (1) PT3067045T (enExample)
RU (1) RU2707748C2 (enExample)
TW (3) TWI691341B (enExample)
WO (1) WO2015068397A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3003920T3 (en) * 2013-11-08 2025-03-11 Activus Pharma Co Ltd Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent
WO2020223158A1 (en) 2019-04-30 2020-11-05 The Medical College Of Wisconsin, Inc. Trans-tympanic membrane delivery platform and uses thereof
CN113484436B (zh) * 2021-07-06 2022-07-12 云南中烟工业有限责任公司 同时测定抑菌纸张中五种禁限用物质含量的方法及其用途
US20230226541A1 (en) * 2022-01-18 2023-07-20 Hollister Incorporated Fluid absorption test tube
US20250367170A1 (en) * 2022-05-24 2025-12-04 The Cleveland Clinic Foundation Topical angiotensin ii receptor blockers (arbs) for treating eye conditions
CN116686841B (zh) * 2023-06-07 2024-07-19 丽珠集团新北江制药股份有限公司 一种含有多烯烃大环内酯类物质的液态组合物的制备方法
WO2024121651A1 (en) * 2023-11-10 2024-06-13 Amiri ِAmir Ali A liquid herbal antibiotic and a powder herbal antibiotic containing a herbal antibacterial formulation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014094A1 (en) 1989-05-26 1990-11-29 Abbott Laboratories Injectable clarithromycin composition
JPH03169807A (ja) 1989-10-30 1991-07-23 Abbott Lab 脂肪親和性薬剤の注射用組成物
WO1998033482A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation
WO2002015878A1 (fr) 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
WO2004006959A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
WO2004050021A2 (en) 2002-11-27 2004-06-17 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2007008537A2 (en) 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
JP2007119456A (ja) 2005-09-30 2007-05-17 Toyama Chem Co Ltd 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20130216609A1 (en) 2008-07-21 2013-08-22 The Regents Of The University Of California Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577742B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
US5085864A (en) 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
CA2591744A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
EP2076244B1 (en) 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
US20080160043A1 (en) * 2007-07-16 2008-07-03 Kim Moo-Sung Preparation method of beta-glucan from schizophyllum commune and composition for external application comprising the same
EP2192887A1 (en) * 2007-08-29 2010-06-09 Agency for Science, Technology And Research Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use
EP2296632A4 (en) 2008-07-14 2014-11-12 Otonomy Inc COMPOSITIONS AND METHODS FOR MODULATING CONTROLLED RELEASE APOPTOSIS FOR THE TREATMENT OF OTIC DISORDERS
EP2335686A1 (en) * 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
BR112014028431B1 (pt) * 2012-05-11 2022-01-11 Activus Pharma Co., Ltd Nanopó de composto orgânico, método para produzir o mesmo e suspensão
ES3003920T3 (en) * 2013-11-08 2025-03-11 Activus Pharma Co Ltd Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014094A1 (en) 1989-05-26 1990-11-29 Abbott Laboratories Injectable clarithromycin composition
JPH03169807A (ja) 1989-10-30 1991-07-23 Abbott Lab 脂肪親和性薬剤の注射用組成物
WO1998033482A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation
WO2002015878A1 (fr) 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
WO2004006959A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
WO2004050021A2 (en) 2002-11-27 2004-06-17 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2007008537A2 (en) 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
JP2007119456A (ja) 2005-09-30 2007-05-17 Toyama Chem Co Ltd 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20130216609A1 (en) 2008-07-21 2013-08-22 The Regents Of The University Of California Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Jonas, J. Kuehne 등, Am J Ophthalmol (2004) 138： 547－553
Joon－Young Hyon 등, Arch Ophthalmol (2004) 122： 1166－1169
Robert H. Gross 등, Invest Ophthalmol Vis Sci (1995) 36(5)： 965－968
Yutaka Inoue 등, International Journal of Pharmaceutics (2007) 331： 38－45

Also Published As

Publication number Publication date
CA2929361A1 (en) 2015-05-14
RU2016122544A (ru) 2017-12-13
TW202027726A (zh) 2020-08-01
AU2014345193A1 (en) 2016-06-02
KR102345084B1 (ko) 2021-12-29
TWI747209B (zh) 2021-11-21
KR20210054068A (ko) 2021-05-12
TW201521785A (zh) 2015-06-16
TWI691341B (zh) 2020-04-21
AU2014345193B2 (en) 2020-03-05
EP3067045A1 (en) 2016-09-14
IL245406A0 (en) 2016-06-30
WO2015068397A1 (ja) 2015-05-14
MX2016005764A (es) 2017-01-05
ES3003920T3 (en) 2025-03-11
PL3067045T3 (pl) 2025-04-07
RU2707748C2 (ru) 2019-11-29
EP3067045B1 (en) 2024-12-04
CN105658203A (zh) 2016-06-08
JP6407882B2 (ja) 2018-10-17
AU2014345193C1 (en) 2020-09-10
US10792248B2 (en) 2020-10-06
PT3067045T (pt) 2025-02-13
EP3067045A4 (en) 2016-11-16
US20160271057A1 (en) 2016-09-22
IL245406B (en) 2021-03-25
TW201828923A (zh) 2018-08-16
JPWO2015068397A1 (ja) 2017-03-09
CA2929361C (en) 2022-05-31
BR112016010358B1 (pt) 2022-07-26
CN105658203B (zh) 2021-03-16
BR112016010358A2 (enExample) 2017-08-08
RU2016122544A3 (enExample) 2018-05-29

Similar Documents

Publication Publication Date Title
US11376262B2 (en) Method of treating an inflammatory or infectious disease
US6277829B1 (en) Process for preparing of aqueous formulation for opthalmic use
KR102345084B1 (ko) 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000